Washington DC-Baltimore Area
Advisor to emerging biotech companies on clinical development planning in neurodegenerative and other neurological diseases.
-Led a team of 10 FTEs and ~10 consultants responsible for medicinal chemistry, in vitro and in vivo pharmacology, translational science, biomarker development, nonclinical development, clinical science, statistics and data management, and regulatory affairs. -Oversaw clinical development of Tranquis’ lead compound, TQS-168, through successful completion of Phase 1, and progression of TQS-621 through IND-enabling studies.
Clinical development of the mitophagy enhancer CAP-1902 for the treatment of neurodegenerative and neuromuscular disorders.
Advised Verge on clinical development plans for ALS